SCHEMBL2239784

SCHEMBL2239784

c1ccc2c(c1)Cc1cnccc1-2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.47
MAOB P27338 1/20 0.47
CYP19A1 P11511 6/20 0.46
TNF P01375 2/20 0.46
PLK4 O00444 1/20 0.46
DAPK3 O43293 1/20 0.46
PIM1 P11309 1/20 0.46
PDGFRA P16234 1/20 0.46
LTK P29376 1/20 0.46
MAP2K2 P36507 1/20 0.46
FLT3 P36888 1/20 0.46
MAPK8 P45983 1/20 0.46
MAPK9 P45984 1/20 0.46
CSNK1A1 P48729 1/20 0.46
TDO2 P48775 1/20 0.46
CDK8 P49336 1/20 0.46
CDK5 Q00535 1/20 0.46
MAP2K1 Q02750 1/20 0.46
MST1R Q04912 1/20 0.46
PTK2 Q05397 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30322772 1.00 MAOA (0.47) MAOAMAOBCYP19A1TNFPLK4
SCHEMBL11369963 0.89 MAOA (0.50) MAOAMAOBCYP19A1TNFPLK4
SCHEMBL29699898 0.89 SIGMAR1 (0.48) MAOAMAOBLMNAMAPTSMN1; SMN2
SCHEMBL14452876 0.89 SIGMAR1 (0.48) MAOAMAOBLMNAMAPTSMN1; SMN2
SCHEMBL23154411 0.88 MAOA (0.67) MAOAMAOBCYP19A1TNFKDM4E
SCHEMBL19051940 0.88 CYP19A1 (0.41) MAOAMAOBCYP19A1TNFPLK4
SCHEMBL3075871 0.87 MAOA (0.47) MAOAMAOBCYP19A1TNFPLK4
SCHEMBL30322863 0.87 MAOA (0.47) MAOAMAOBCYP19A1TNFPLK4
SCHEMBL11559098 0.85 MAOA (0.45) MAOAMAOBCYP19A1TNFPLK4
SCHEMBL8618246 0.84 SIGMAR1 (0.46) MAOAMAOBCYP19A1TNFKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1923387-B1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2011-10-19 EP claimed
US-20100168096-A1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-07-01 US claimed
EP-1923387-A1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-05-21 EP claimed
EP-0698226-A4 COMPLEMENTARY SURFACE CONFINED POLYMER ELECTROCHROMIC MATERIALS, SYSTEMS, AND METHODS OF FABRICATION THEREFOR IGEN INC (US) 1997-02-12 EP claimed
EP-0698226-A1 COMPLEMENTARY SURFACE CONFINED POLYMER ELECTROCHROMIC MATERIALS, SYSTEMS, AND METHODS OF FABRICATION THEREFOR IGEN, INCORPORATED (US) 1996-02-28 EP claimed
US-11818949-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-11-14 US disclosed
US-20230157166-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT CANON KABUSHIKI KAISHA (JP) 2023-05-18 US disclosed
US-20230131934-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-04-27 US disclosed
WO-2020125589-A1 PHOSPHINE OXIDE GROUP-CONTAINED TRANSITION METAL COMPLEX, AND POLYMER, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE THEREOF 广州华睿光电材料有限公司 2020-06-25 WO disclosed
EP-3242872-B1 (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER GENENTECH INC (US) 2019-07-03 EP disclosed
US-20180226580-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION 2018-08-09 US disclosed
US-20180212158-A1 ORGANIC LIGHT-EMITTING DIODE MATERIALS PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2018-07-26 US disclosed
US-5070100-A COMPLICATIONS OF DIABETES ALCON LABORATORIES, INC. (US) 1991-12-03 US disclosed
US-4864028-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1989-09-05 US disclosed
EP-0311010-A2 Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1989-04-12 EP disclosed
US-4605660-A INHIBIT CONTRACTION OF SMOOTH MUSCLE MERCK & CO., INC. (US) 1986-08-12 US disclosed
US-4605660-A INHIBIT CONTRACTION OF SMOOTH MUSCLE MERCK & CO., INC. (US) 1986-08-12 US disclosed
US-4605660-A INHIBIT CONTRACTION OF SMOOTH MUSCLE MERCK & CO., INC. (US) 1986-08-12 US disclosed
US-4537892-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1985-08-27 US disclosed
EP-0137333-A2 Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase ALCON LABORATORIES, INC. (US) 1985-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180212158-A1 ORGANIC LIGHT-EMITTING DIODE MATERIALS MSN, DDT, NECTIN4 MAOA 175/4885MAOB 55/4885CYP19A1 2096/4885
US-20230131934-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, OCIAD2, OSBP MAOA 1466/4885MAOB 892/4885CYP19A1 2201/4885
US-11818949-B2 Organic electroluminescent materials and devices EML4, TBCB, TERF2IP MAOA 679/4885MAOB 284/4885CYP19A1 3908/4885
US-20180226580-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SLCO4C1, SLCO2A1, SLCO2B1 MAOA 1810/4885MAOB 910/4885CYP19A1 747/4885
US-20230157166-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT OR10J3, OR51E2, OLA1 MAOA 1453/4885MAOB 773/4885CYP19A1 250/4885
US-20100168096-A1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF HTR2B, HTR7, HTR3B MAOA 553/4885MAOB 187/4885CYP19A1 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.